The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate-risk disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate-risk disease

Published:2014-03-06 Issue:12 Volume:120 Page:1787-1793
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Keane Florence K.¹,Chen Ming-Hui²,Zhang Danjie²,Loffredo Marian J.³,Kantoff Philip W.⁴,Renshaw Andrew A.⁵,D'Amico Anthony V.³

Affiliation:

1. Harvard Radiation Oncology Program; Harvard Medical School; Boston Massachusetts

2. Department of Statistics; University of Connecticut; Storrs Connecticut

3. Department of Radiation Oncology; Dana Farber Cancer Institute and Brigham and Women's Hospital; Boston Massachusetts

4. Department of Medical Oncology; Dana Farber Cancer Institute and Brigham and Women's Hospital; Boston Massachusetts

5. Department of Pathology; Baptist Hospital of Miami; Miami Florida

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference43 articles.

1. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era;D'Amico;Cancer,2002

2. NCCN clinical practice guidelines in oncology: prostate cancer;Mohler;J Natl Compr Canc Netw,2010

3. A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy;Zumsteg;Eur Urol,2013

4. Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors;Nguyen;Int J Radiat Oncol Biol Phys,2009

5. Dose escalation with 3-dimensional conformal radiation therapy affects the outcome in prostate cancer;Zelefsky;Int J Radiat Oncol Biol Phys,1998

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Short-term Darolutamide (ODM-201) Concomitant to Radiation Therapy for Patients with Unfavorable Intermediate-risk Prostate Cancer: The Darius (AFU-GETUG P15) Phase 2 Trial Protocol;European Urology Oncology;2024-05

2. French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Diagnosis and management of localised disease;Progrès en Urologie;2022-11

3. The Impact of Gleason Grade 3 as a Predictive Factor for Biochemical Recurrence after Robot-Assisted Radical Prostatectomy: A Retrospective Multicenter Cohort Study in Japan (The MSUG94 Group);Medicina;2022-07-25

4. Grade and stage misclassification in intermediate unfavorable‐risk prostate cancer radiotherapy candidates;The Prostate;2022-04

5. Personalization of Treatment Intensity for Intermediate-Risk Prostate Cancer;International Journal of Radiation Oncology*Biology*Physics;2022-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3